Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.